Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Boston Scientific Corporation stock

Own Boston Scientific Corporation stock in just a few minutes.

Boston Scientific Corporation is a medical devices business based in the US. Boston Scientific Corporation shares (BSX) are listed on the NYSE and all prices are listed in US Dollars. Boston Scientific Corporation employs 38,000 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Boston Scientific Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BSX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Boston Scientific Corporation share price

Use our graph to track the performance of BSX stocks over time.

Boston Scientific Corporation shares at a glance

Information last updated 2021-04-30.
52-week range$32.99 - $44.63
50-day moving average $39.66
200-day moving average $37.30
Wall St. target price$49.04
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $2.61

Buy Boston Scientific Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Boston Scientific Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Boston Scientific Corporation under- or over-valued?

Valuing Boston Scientific Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Boston Scientific Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Boston Scientific Corporation's PEG ratio

Boston Scientific Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.2781. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Boston Scientific Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Boston Scientific Corporation's EBITDA

Boston Scientific Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.3 billion.

The EBITDA is a measure of a Boston Scientific Corporation's overall financial performance and is widely used to measure a its profitability.

Boston Scientific Corporation financials

Revenue TTM $9.9 billion
Operating margin TTM 11.39%
Gross profit TTM $6.8 billion
Return on assets TTM 2.3%
Return on equity TTM -0.56%
Profit margin -0.83%
Book value $10.82
Market capitalisation $62.6 billion

TTM: trailing 12 months

Shorting Boston Scientific Corporation shares

There are currently 14.6 million Boston Scientific Corporation shares held short by investors – that's known as Boston Scientific Corporation's "short interest". This figure is 17.8% down from 17.8 million last month.

There are a few different ways that this level of interest in shorting Boston Scientific Corporation shares can be evaluated.

Boston Scientific Corporation's "short interest ratio" (SIR)

Boston Scientific Corporation's "short interest ratio" (SIR) is the quantity of Boston Scientific Corporation shares currently shorted divided by the average quantity of Boston Scientific Corporation shares traded daily (recently around 6.4 million). Boston Scientific Corporation's SIR currently stands at 2.29. In other words for every 100,000 Boston Scientific Corporation shares traded daily on the market, roughly 2290 shares are currently held short.

However Boston Scientific Corporation's short interest can also be evaluated against the total number of Boston Scientific Corporation shares, or, against the total number of tradable Boston Scientific Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Boston Scientific Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Boston Scientific Corporation shares in existence, roughly 10 shares are currently held short) or 0.0103% of the tradable shares (for every 100,000 tradable Boston Scientific Corporation shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Boston Scientific Corporation.

Find out more about how you can short Boston Scientific Corporation stock.

Boston Scientific Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Boston Scientific Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Boston Scientific Corporation's total ESG risk score

Total ESG risk: 29.23

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Boston Scientific Corporation's overall score of 29.23 (as at 12/31/2018) is nothing to write home about – landing it in it in the 57th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Boston Scientific Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Boston Scientific Corporation's environmental score

Environmental score: 1.51/100

Boston Scientific Corporation's social score

Social score: 12.87/100

Boston Scientific Corporation's governance score

Governance score: 7.87/100

Boston Scientific Corporation's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Boston Scientific Corporation scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Boston Scientific Corporation hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Boston Scientific Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 29.23
Total ESG percentile 56.94
Environmental score 1.51
Social score 12.87
Governance score 7.87
Level of controversy 3

Boston Scientific Corporation share dividends

We're not expecting Boston Scientific Corporation to pay a dividend over the next 12 months.

Have Boston Scientific Corporation's shares ever split?

Boston Scientific Corporation's shares were split on a 2:1 basis on 5 November 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Boston Scientific Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Boston Scientific Corporation shares which in turn could have impacted Boston Scientific Corporation's share price.

Boston Scientific Corporation share price volatility

Over the last 12 months, Boston Scientific Corporation's shares have ranged in value from as little as $32.99 up to $44.63. A popular way to gauge a stock's volatility is its "beta".

BSX.US volatility(beta: 0.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Boston Scientific Corporation's is 0.8384. This would suggest that Boston Scientific Corporation's shares are less volatile than average (for this exchange).

Boston Scientific Corporation overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site